What Vayamed does

Vayamed GmbH is a Berlin-based pharmaceutical wholesaler, incorporated in 2024 as a subsidiary of Sanity Group, that distributes standardized cannabinoid-based medicines to registered pharmacies and physicians across Germany. The company's product portfolio spans pharmaceutical-grade CBD isolate, Dronabinol (synthetic THC), medical cannabis flowers including Bedrocan 22:1 and the newly introduced Bedrocan Forte 25:1, and full-spectrum extracts, all manufactured and distributed under GMP and GDP quality standards. Vayamed holds regulatory authorization from LAGeSo Berlin and the Bundesopiumstelle, and operates a DocCheck-authenticated Fachbereich (specialist) portal that gates product information and ordering behind healthcare professional verification per §10 Heilmittelwerbegesetz. The firm is also the exclusive German wholesale partner for Bedrocan, integrated with Medios AG and Cannaflos for nationwide distribution.

The business model is B2B wholesale and professional services: revenue is generated through transactional product sales to registered pharmacies and healthcare professionals (14-day net payment, 2% skonto for SEPA direct debit within 7 days, no minimum order quantity, free shipping within Germany), supplemented by professional consultation services delivered on-site, by phone, and via digital appointments. Complementary services include the free Vayamed Cannabisausweis (patient ID card) for therapy documentation, CME-certified physician education through the DGS 'Schmerzkompetenz Cannabis' curriculum, and ongoing medical-evidence support including sponsorship of the Charité Berlin EXCARP observational study. The company serves three primary customer segments — patients with chronic or neuropathic pain, prescribing physicians and pain specialists, and dispensing pharmacies — and benefits from the April 2024 MedCanG reclassification of medical cannabis from narcotic to prescription-only status, which expanded the addressable prescribing base to approximately 76,000 contract physicians in Germany.

Name

Vayamed

Legal name

Vayamed GmbH

Website

https://vayamed.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Short description

Vayamed GmbH is a Berlin-based pharmaceutical wholesaler, subsidiary of Sanity Group, that distributes GMP/GDP-certified cannabinoid medicines (CBD isolate, Dronabinol, Bedrocan flowers, extracts) to registered pharmacies and physicians across Germany.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals / Medical Cannabis Distribution

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (42421), Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services) (CRANAFAI)

akta.pro secondary industry

Medical Cannabis Dispensaries (CRANAFAB)

Keywords

• Medical cannabis wholesale
• Cannabinoid pharmaceuticals
• Pharmaceutical distribution
• Medical cannabis therapy
• Specialty pharma Germany

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Pharmaceutical Wholesale - Medical Cannabis Products: Wholesale distribution of standardized cannabinoid-based pharmaceuticals including CBD isolate, Dronabinol, medical cannabis flowers, and full-spectrum extracts to registered pharmacies and healthcare professionals in Germany.
2. Professional Consultation Services: Consultation services for healthcare professionals including on-site consultations, telephone professional support, and online professional section with information and training materials.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Vayamed GmbH manufactures and distributes a portfolio of standardized, GMP/GDP-compliant cannabinoid-based pharmaceutical products—including CBD isolate, Dronabinol, medical cannabis flowers, and full-spectrum extracts—to registered pharmacies and licensed physicians across Germany. Alongside the pharmaceutical line, the company sells a free Vayamed Cannabisausweis (patient ID card) for therapy documentation and provides professional consultation and education services to prescribers and pharmacists through its specialist portal and account-managed relationships.

Product overview

Vayamed offers a patient-oriented portfolio of standardized cannabinoid-based pharmaceuticals and related services. The core product range includes pharmaceutical-grade CBD isolate, dronabinol (synthetic THC), medical cannabis flowers (Bedrocan® varieties), and full-spectrum extracts—all manufactured according to GMP and GDP quality standards. The product line was expanded in 2026 to include Bedrocan® Forte 25:1 and Bedrocan® 22:1 cannabis flowers through an exclusive distribution partnership. Complementary services include the Vayamed Cannabisausweis (patient ID card) for therapy documentation, a specialist Fachbereich portal with product information and ordering, and medical/pharmaceutical education support through partnerships with DGS and other professional organizations.

Differentiator

Problem solved

Functional benefit

Products and services

• CBD Isolate (CBD-Isolat) Pharmaceutical-grade CBD isolate cannabinoid product manufactured to GMP/GDP quality standards for therapeutic use in cannabinoid-based therapy.
• Dronabinol Synthetic THC (tetrahydrocannabinol) pharmaceutical product for cannabinoid-based therapy, supplied to pharmacies and licensed prescribers in Germany.
• Medical Cannabis Flowers (Medizinisch relevante Cannabisblüten) Standardized pharmaceutical-quality cannabis flowers for medical use, supplied by Vayamed to registered pharmacies and licensed physicians in Germany.
• Full-Spectrum Extracts (Vollspektrumextrakte) Full-spectrum cannabinoid extracts containing multiple cannabis compounds, manufactured to GMP/GDP standards for enhanced therapeutic effects.
• Bedrocan® 22:1 Established Dutch-origin Bedrocan medical cannabis flower with a 22% THC and 1% CBD ratio, distributed by Vayamed in Germany under its exclusive Bedrocan wholesale partnership.
• Bedrocan® Forte 25:1 Higher-dosage Bedrocan medical cannabis flower (25% THC, 1% CBD) developed for patients requiring stronger cannabinoid therapy; introduced to the German market in April 2026 under Vayamed's exclusive Bedrocan wholesale partnership.
• Vayamed Cannabisausweis (Patient ID Card) Free personalized patient identification card certifying authorized use of prescribed cannabinoid medications, intended to support patients during police controls and document ongoing therapy.

Quantifiable outcome

• 74% of patients reported improvement in symptoms and quality of life in BfArM observational study
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature2 records

Partnerships

Eight partnerships are on record, tiered core, major and minor.

• Sanity GroupcoreStrategic or Co-development Partner · 23 April 2026Parent company of Vayamed GmbH. Vayamed operates as a subsidiary specializing in medical cannabinoid products. Sanity Group founder Finn Hänsel serves as managing director of Vayamed.
• Medios AGcoreChannel Partner/ Reseller/ Distributor · 23 April 2026Leading Specialty Pharma provider in Europe, exclusive distribution partner of Bedrocan for Germany since 2026. Vayamed integrated as exclusive wholesale partner within their distribution network alongside Cannaflos.
• Cannaflos - Gesellschaft für medizinisches Cannabis mbHmajorChannel Partner/ Reseller/ Distributor · 23 April 2026Distribution partner supporting Medios AG in building nationwide distribution network in Germany. Works with Vayamed as exclusive wholesale partner within the distribution chain.
• BedrocanmajorTechnology or Integration · 23 April 2026Dutch manufacturer of standardized medical cannabis products. Vayamed distributes Bedrocan products including Bedrocan 22:1 and Bedrocan Forte 25:1 cannabis flowers in Germany.
• Bundesverband der Pharmazeutischen Industrie (BPI)minorOthersGerman pharmaceutical industry association advocating for policy supporting pharmaceutical innovation and sustainable healthcare. Vayamed holds membership.
• Deutsche Gesellschaft für Schmerzmedizin e.V. (DGS)coreStrategic or Co-development PartnerLargest medical pain therapy society in Europe. Vayamed is the only pharmaceutical company supporting the DGS Pain Initiative Cannabinoids and sponsoring DGS Curriculum 'Schmerzkompetenz Cannabis' with scholarships.
• Deutsche Schmerzliga e.V.minorOthersPatient organization for chronic pain patients advocating for quality pain therapy and patient rights to competent treatment. Vayamed maintains partnership.
• Charité Berlin / Immanuel Krankenhaus BerlinmajorStrategic or Co-development PartnerVayamed supported the EXCARP observational study conducted by Charité Hochschulambulanz für Naturheilkunde examining patient perspectives on prescription cannabinoid therapies.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Nimbus Health (now part of Cansativa): German medical cannabis wholesaler and pharmacy platform offering standardized cannabis products and digital ordering tools. Competes with Vayamed in the same physician/pharmacy channel and has been active in advocating for streamlined German cannabis prescribing frameworks.
• Remexian Pharma (High Tide): High Tide's German subsidiary actively competes with Vayamed in medical cannabis wholesale to German pharmacies. Notable as Vayamed's most direct legal adversary in the Berlin Court injunction case, indicating direct competition in physician and pharmacy channels for standardized medical cannabis products.
• Cannamedical Pharma: Germany-based medical cannabis wholesaler with similar GACP/GMP-certified product portfolio and pharmacy distribution model. Operates as a direct competitor in supplying standardized cannabis flowers and extracts to German pharmacies, with comparable focus on physician education.
• Demecan: Vertically integrated German medical cannabis producer-distributor cultivating domestically and wholesaling standardized flower products to German pharmacies. Directly competes with Vayamed's imported flower portfolio with a 'Made in Germany' positioning advantage.

Others

• Avaay (Sanity Group): Sister brand of Vayamed under the Sanity Group umbrella, focused on medical cannabis e-commerce. Operates the Apo Online Shop accessed via vayamed.com and represents the parent group's adjacent channel rather than a direct competitor.
• Storz & Bickel GmbH (Canopy Growth): German vaporizer manufacturer that is both a Vayamed technology/integration partner and part of Canopy Growth. Provides medical devices for cannabinoid administration and represents a complementary, not directly competitive, player in the German medical cannabis ecosystem.
• Bedrocan International: Dutch producer of standardized medical cannabis flowers and Vayamed's exclusive German wholesale partner. Closely economically linked but operates upstream of Vayamed; relevant for understanding Vayamed's product differentiation and supply continuity risks.

Broad incumbents

• Canopy Growth Corporation: Canadian cannabis multinational with established German medical cannabis operations via its Storz & Bickel vaporizer subsidiary partnership network. Competes with Vayamed in the broader medical cannabis and cannabinoid therapy ecosystem in Germany.
• Aurora Cannabis: Large Canadian cannabis producer with established European medical cannabis operations, including Germany. Competes with Vayamed in the wholesale supply of standardized medical cannabis flowers to German pharmacies and leverages its vertically integrated cultivation footprint similar to Vayamed's partnership with Bedrocan.
• Tilray Brands: Global cannabis leader with significant German medical cannabis distribution operations. Competes directly with Vayamed in the German pharmacy wholesale channel and offers a comparable portfolio of standardized medical cannabis flowers and extracts, but at much larger scale and broader geographic footprint.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat4 records

Key risks4 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/Vayamed
• Instagraminstagram.com/vayamed_official
• LinkedInlinkedin.com/company/vayamed

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vayamed